WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 20, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced new data presentations on EDP-305, Enanta`s lead Farnesoid X receptor (FXR) agonist being developed for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), will be presented at The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place October 20-24, 2017 in Washington, D.C. EDP-305 has demonstrated potency and efficacy in a variety of NASH, fibrosis and...
|